Journal of Applied Physiology Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 77: 397-405, 1994;
8750-7587/94 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowden, J. J.
Right arrow Articles by McDonald, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowden, J. J.
Right arrow Articles by McDonald, D. M.

Journal of Applied Physiology, Vol 77, Issue 1 397-405, Copyright © 1994 by American Physiological Society


ARTICLES

Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol

J. J. Bowden, I. Sulakvelidze and D. M. McDonald
Cardiovascular Research Institute, University of California, San Francisco 94143.

Many inflammatory mediators trigger the adhesion of leukocytes to the vascular endothelium. We sought to determine whether the beta 2-adrenergic receptor agonist formoterol can inhibit the adhesion of neutrophils and eosinophils to the endothelium of venules in the rat airway mucosa. We also tested whether this action is mediated by beta 2-adrenergic receptors. Inflammation was induced in the airways of anesthetized pathogen-free F344 rats by injecting substance P (5 micrograms/kg) or bradykinin (10 mg/kg) intravenously. The rats were perfused with fixative 5 min later, and the tracheas were removed. Adherent intravascular neutrophils and eosinophils, stained by a histochemical reaction for myeloperoxidase, were counted in tracheal whole mounts. We found that, after the injection of substance P, formoterol (0.1, 1.0, or 10.0 micrograms/kg i.v.) reduced the number of adherent neutrophils by 8, 59, or 56% and reduced the number of eosinophils by 59, 90, or 86%, respectively. The three doses of formoterol reduced the amount of substance P-induced extravasation of Monastral blue by 21, 66, or 80%, respectively. Both effects of formoterol were blocked by the beta 2-adrenergic receptor antagonist ICI-118,551, which by itself produced neither leukocyte adhesion nor plasma extravasation. After the injection of bradykinin, the three doses of formoterol reduced the number of adherent neutrophils by 28, 67, or 62% and reduced the number of eosinophils by 17, 38, or 57%, respectively. We conclude that formoterol, acting via beta 2-adrenergic receptors, not only can reduce the amount of plasma leakage but also can reduce the number of neutrophils and eosinophils that adhere to the vascular endothelium at sites of inflammation.


This article has been cited by other articles:


Home page
ChestHome page
K. Maneechotesuwan, S. Essilfie-Quaye, S. Meah, C. Kelly, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes
Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma
Chest, October 1, 2005; 128(4): 1936 - 1942.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. E. Hegab, T. Sakamoto, W. Saitoh, H. H. Massoud, H. M. Massoud, K. M. Hassanein, and K. Sekizawa
Polymorphisms of IL4, IL13, and ADRB2 Genes in COPD
Chest, December 1, 2004; 126(6): 1832 - 1839.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Cazzola and R. Dahl
Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD
Chest, July 1, 2004; 126(1): 220 - 237.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin
Formoterol protects against platelet-activating factor-induced effects in asthma
Eur. Respir. J., January 1, 2004; 23(1): 71 - 75.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P.J. Barnes
Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids
Eur. Respir. J., January 1, 2002; 19(1): 182 - 191.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]


Home page
ChestHome page
M. Johnson and S. Rennard
Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD
Chest, July 1, 2001; 120(1): 258 - 270.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. He, J. Wang, and M. Zeng
Leukocyte adhesion and microvessel permeability
Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1686 - H1694.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. A. Giembycz and M. A. Lindsay
Pharmacology of the Eosinophil
Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. H. K. Lim, B. S. Bochner, and E. M. Wagner
Leukocyte recruitment in the airways: an intravital microscopic study of rat tracheal microcirculation
Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L959 - L967.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online